Vitiligo happens when your immune system destroys the cells that produce skin pigment. These cells, called melanocytes, are attacked and killed primarily by a specific type of white blood cell, leaving behind smooth white patches that can appear anywhere on the body. The condition affects roughly 0.1% to 1.2% of people worldwide, depending on the region, and onset typically occurs between the ages of 10 and 30.
The process isn’t a single event but a chain reaction. Stress on melanocytes triggers the immune system, which then escalates the damage far beyond what the original stress caused. Understanding each link in that chain helps explain why vitiligo behaves the way it does.
Melanocyte Stress Starts the Process
Melanocytes are under more internal pressure than most cells in your body. The process of making melanin, your skin’s pigment, naturally generates reactive oxygen species (ROS), which are unstable molecules that can damage cells. Normally, your body’s antioxidant system neutralizes these molecules before they cause harm. In people who develop vitiligo, that system is compromised.
In vitiligo-affected skin, key protective enzymes are downregulated. The body’s first line of defense against oxidative damage, a molecule called glutathione, gets depleted. When that happens, a cascade of failures follows: hydrogen peroxide accumulates, proteins are damaged, and melanocytes start dying. The cell death can happen through several pathways, including a form called ferroptosis, where iron-dependent reactions cause fats in the cell membrane to break down. Research on vitiligo patients consistently shows reduced levels of the enzyme that prevents ferroptosis, both in affected skin and in blood samples.
This oxidative stress doesn’t just kill melanocytes directly. It sets off something more damaging: the dying cells release fragments that the immune system recognizes as threats.
The Immune System Takes Over
Once stressed melanocytes begin releasing cellular debris, the immune system treats those fragments as foreign invaders. Immune cells called dendritic cells and macrophages pick up the melanocyte fragments, process them, and present them to the adaptive immune system. This is where the damage escalates dramatically.
The key players in melanocyte destruction are CD8+ cytotoxic T cells, a type of white blood cell designed to kill targeted cells. These T cells home in on melanocytes and destroy them through two main mechanisms: they release enzymes that punch holes in the melanocyte membrane, and they activate a death-signaling pathway on the melanocyte surface. The result is the same either way. The melanocyte dies.
These killer T cells also release a signaling molecule called interferon-gamma, which does three things simultaneously. It recruits even more T cells to the area, creating a feedback loop that amplifies the attack. It acts as a direct toxin to melanocytes at high local concentrations while leaving surrounding skin cells unharmed. And it causes nearby skin cells to release chemical signals that further attract immune cells. This is why vitiligo patches can expand over time: each wave of melanocyte death generates signals that draw more immune cells to neighboring skin.
Some of these T cells become resident memory cells that remain in previously affected skin long after the white patches form. This helps explain why vitiligo patches tend to recur in the same locations, and why repigmented areas can lose color again.
Genetics Load the Gun
Vitiligo is not caused by a single gene. Instead, dozens of genetic variations each contribute a small amount of risk. Many of these genes fall into two categories: those that regulate the immune system and those that affect melanocyte function.
On the immune side, several vitiligo-associated genes are the same ones linked to other autoimmune diseases like type 1 diabetes and rheumatoid arthritis. Variations in genes that control T cell activation make it easier for the immune system to mount an attack against the body’s own cells. Variations in genes involved in antigen presentation, the process by which immune cells identify targets, increase the expression of the proteins that flag melanocytes for destruction.
On the melanocyte side, one of the most interesting findings involves the gene for tyrosinase, the enzyme melanocytes use to make pigment. The vitiligo-associated variants of this gene actually reduce the enzyme’s stability and function. Paradoxically, these variants are considered protective against melanoma because they make melanocytes less active. The flip side is that these less-stable proteins may be more prone to misfolding under stress, generating the cellular debris that triggers immune recognition.
Another gene linked to vitiligo encodes a protein involved in inflammasome regulation, part of the innate immune system. Vitiligo-associated variants cause this protein to be constitutively active, meaning the inflammatory alarm is always partially turned on.
Environmental Triggers
Genetics create susceptibility, but something in the environment usually tips the balance. One well-documented trigger is skin injury, known in dermatology as the Koebner phenomenon. Cuts, burns, friction, sunburn, and even chronic pressure can trigger new vitiligo patches in people who are genetically predisposed. Physical trauma increases hydrogen peroxide levels in the skin, which damages proteins and causes melanocytes to release stress proteins. These stress proteins are highly immunogenic, meaning they provoke a strong immune response and can kickstart the autoimmune cycle.
Chemical exposure is another trigger. Certain phenol-containing compounds found in hair dyes, rubber products, and industrial chemicals can be directly toxic to melanocytes. Emotional and psychological stress also plays a documented role. Stress hormones like epinephrine and norepinephrine are elevated in vitiligo patients compared to healthy controls. These catecholamines contribute to depigmentation in multiple ways: they promote hydrogen peroxide production, they constrict blood vessels (reducing oxygen supply to the skin), and their breakdown products directly interfere with melanin production. Compounds called biopterins, which accumulate alongside elevated catecholamines, inhibit the very enzymes melanocytes need to produce pigment.
Two Types, Two Patterns
Vitiligo comes in two main forms that behave quite differently. Non-segmental vitiligo is the more common type. It produces patches that tend to appear symmetrically on both sides of the body, often on the hands, face, and areas around body openings. It evolves over time, with patches slowly expanding and new ones appearing. Hair in affected areas usually stays pigmented, at least early on. This type is strongly driven by autoimmune mechanisms.
Segmental vitiligo affects only one side or one section of the body. It typically appears earlier in life, spreads rapidly within its segment over 6 to 24 months, and then stops. Up to 50% of people with segmental vitiligo develop white hair in the affected area early in the disease. The exact mechanism driving its distribution pattern is still debated, though some evidence points to a neurogenic component, with nerve-related chemical signals contributing to melanocyte loss in a localized area. Some people develop mixed vitiligo, where segmental patches appear first and non-segmental patches follow months or years later.
Linked Autoimmune Conditions
Because vitiligo involves immune system dysregulation, it frequently occurs alongside other autoimmune conditions. Thyroid disease is the most common association. A meta-analysis of over 78,000 vitiligo patients found that 15.7% had thyroid disease, and about 17% tested positive for thyroid-targeting antibodies even without overt thyroid symptoms. Alopecia areata, an autoimmune form of hair loss, is the second most common associated condition, occurring in roughly 4% of vitiligo patients.
How Vitiligo Is Treated
Treatment focuses on calming the immune attack and encouraging melanocytes to repopulate depigmented skin. Narrowband UVB phototherapy has been a first-line option for widespread vitiligo for years. It works by stimulating melanocyte precursors in hair follicles to migrate into surrounding skin, which is why repigmentation often starts as small dots of color around hair follicles within white patches. It’s typically combined with other treatments to improve results.
A newer option is a topical cream containing a JAK inhibitor, approved for non-segmental vitiligo with facial involvement in adults and adolescents 12 and older. JAK inhibitors work by blocking the signaling pathway that interferon-gamma uses to recruit and activate the T cells attacking melanocytes. In clinical use, facial skin tends to respond best, likely because of the density of hair follicles providing a reservoir of melanocyte precursors. Depigmentation can return after stopping treatment, reflecting the persistent presence of memory T cells in the skin. Older options include topical corticosteroids and calcineurin inhibitors, which suppress local immune activity, as well as surgical techniques that transplant melanocytes from unaffected skin into stable white patches.